Wall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV)

​Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the Best Growth Stocks Under $25 to Buy Right Now. Wall Street has a mixed opinion on Roivant Sciences Ltd. (NASDAQ:ROIV) since the company announced positive results from its Phase 3 VALOR study testing Brepocitinib in dermatomyositis on September 17.

​On October 8, Brian Cheng from J.P. Morgan reiterated a Buy rating on Roivant Sciences Ltd. (NASDAQ:ROIV) with a price target of $20. However, earlier on September 24, Chi Meng Fong from Bank of America Securities had reiterated a Hold rating on the stock with a $16.5 price target.

​Fong noted the company has shown promising progress in its Phase 3 VALOR study. However, he anticipates the launch targeting only a limited referral center, thereby limiting the immediate growth potential as well.

​Moreover, Fong also noted that while the company remains confident in the development of IMVT-1402 for Graves’ disease and other autoimmune diseases, he highlights that the market remains competitive. The analyst also raised his concern about the LNP litigation against major players, including Pfizer and Moderna, noting that adverse outcomes from the litigation could potentially impact Roivant Sciences Ltd.’s (NASDAQ:ROIV) financial health.

​Roivant Sciences Ltd. (NASDAQ:ROIV) is a biotechnology company that focuses on accelerating the development and commercialization of important medicines.

While we acknowledge the potential of ROIV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.